SEC Form 4 · accession 0001140361-17-046253
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Abdun-Nabi
Officer — President & CEO · Director
Period of report
Dec 13, 2017
Accepted (ET)
Dec 14, 2017 · 4:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 13, 2017 | M | 20,000 | $14.44 | A | 224,134 | D | |
| Common StockF1,F2 | Dec 13, 2017 | S | 20,000 | $45.99 | D | 204,134 | D | |
| Common StockF3 | holding | — | — | — | 1,000 | I | By Son |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4,F5 | $14.44 | Dec 13, 2017 | M | 20,000 | D | — | Mar 12, 2019 | Common Stock | 20,000 | 21,906 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.24, inclusive.
- F3The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- F4Consists of an option granted under the company's stock incentive plan as amended and restated.
- F5The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.